

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

47

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/10, C12Q 1/68		A1	(11) International Publication Number: WO 96/40901 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/07082 (22) International Filing Date: 14 May 1996 (14.05.96)		(81) Designated States: AU, CA, JP, KR.	
(30) Priority Data: 08/476,625 7 June 1995 (07.06.95) US 08/477,228 7 June 1995 (07.06.95) US 08/484,519 7 June 1995 (07.06.95) US 08/484,668 7 June 1995 (07.06.95) US 08/484,816 7 June 1995 (07.06.95) US		<p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
(71) Applicant: GEN-PROBE INCORPORATED [US/US]; 9880 Campus Point Drive, San Diego, CA 92121 (US).			
(72) Inventors: DATTAGUPTA, Nanibhusan; 4221 Kerwood Court, San Diego, CA 92130 (US). KACIAN, Daniel, Louis; 3911 Tambor Road, San Diego, CA 92124 (US). LACKEY, David, Bruce; 9496 Babauta Road, San Diego, CA 92129 (US).			
(74) Agents: SCHNEIDER, Carol, A. et al.; Lyon & Lyon, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).			

(54) Title: TEMPLATE AND PRIMER BASED SYNTHESIS OF ENZYMATICALLY CLEAVABLE OLIGONUCLEOTIDES

(57) Abstract

The present invention relates to methods of enzymatically synthesizing chirally pure oligonucleotides. In particular, it relates to methods of enzymatically synthesizing oligonucleotides using optionally digestible templates which are capable of directing the synthesis of an oligonucleotide product which can optionally be cleaved into two or more individual oligonucleotides, optionally using 3'-ribonucleotide primers. In this manner, more than one oligonucleotide having the same or different length and/or sequence can be simultaneously synthesized. The oligonucleotides optionally have at least one phosphorothioate linkage, and contain certain restriction endonuclease recognition sites herein identified as cleavable within phosphorothioate oligonucleotides, thus facilitating the separation and purification of the oligonucleotides after synthesis.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australis	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroun	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

DESCRIPTIONTemplate and Primer Based Synthesis of Enzymatically Cleavable OligonucleotidesField of the Invention

The present invention relates to methods of synthesizing oligonucleotides. In particular, it relates to methods of enzymatically synthesizing oligonucleotides 5 using templates and/or 3'-ribonucleotide primers. Additionally, it relates to the enzymatic cleavage with restriction endonucleases of phosphorothioate-containing nucleic acids.

Background of the Invention

10 Nucleic acids are linear polymers consisting of individual nucleotide subunits which are covalently linked together via phosphodiester bonds. Oligonucleotides are now widely used in the biomedical field as nucleic acid sequencing primers, diagnostic probes and modulators of 15 gene function. One of the most promising uses of oligonucleotides is in the field of antisense therapeutics.

10 Oligonucleotides can be conveniently synthesized using enzymatic or chemical methods, with the latter generally providing for larger scale production than the 20 former. One of the most widely used methods of chemically synthesizing oligonucleotides is based on phosphoramidite solid-phase chemistry (See *Methods in Molecular Biology*, Volume 20: *Protocols for Oligonucleotides and Analogs*, S. Agrawal editor, Humana Press Inc., Totowa, N.J., 437-463 25 (1993)) Now fully automated, this method can be used to chemically produce oligonucleotides in commercial quantities. (See *Oligonucleotides and Analogues: A Practical Approach*. Edited by F. Eckstein, I.R.L. Press, Oxford, England, 1-24 (1991).)

30 Despite the convenience of chemical synthesis, the number of steps and the harshness of the chemicals

involved leads to the formation of a product which may contain toxic chemical impurities, such as damaged nucleotide bases. Because the level of impurities is normally relatively low, chemically synthesized 5 oligonucleotides are still suitable for use in many different applications. However, certain applications require a product which is substantially free of chemical impurities. In particular, when the application involves a biological system, the presence of chemical impurities 10 can have a deleterious effect. Moreover, when the application involves an *in vivo* therapeutic agent, chemical purity is essential. Enzymatic synthesis, which can be used to produce an oligonucleotide product in an aqueous solution that is essentially free of toxic 15 chemical impurities and hazardous byproducts is thus preferred for these applications.

The use of oligonucleotides in biological systems is also compromised by the presence of nucleases which catalyze the breakdown of nucleic acids by hydrolysis of 20 phosphodiester bonds (See *The Biochemistry of the Nucleic Acids: Chapter 4, Degradation and Modification of Nucleic Acids*, Roger L.P. Adams et al., Chapman & Hall, London, England, 97-108 (1992)). Such a breakdown can cause a significant reduction in the biological activity of 25 oligonucleotides *in vivo* thus resulting in diminished therapeutic effectiveness. This degradation can be controlled by modifying or substituting the phosphodiester bonds with a more nuclease-resistant analog, such as phosphotriester, phosphorothioate or methylphosphonate.

30 Phosphorothioate-containing oligonucleotides efficiently resist degradation by many nucleases, and are thus preferred for use in some biological systems. Phosphorothioate linkages have a sulfur in place of oxygen as one of the non-bridging atoms bonded to phosphorous. 35 This substitution produces chirality at the phosphorous which is designated as having either the *Rp* or *Sp* diastereomer orientation. Since the chiral orientation is

an important factor which influences duplex structure, enzyme recognition, conformation and/or hybridization kinetics, it is desirable to use chirally pure phosphorothioate-containing oligonucleotides. Other 5 modified oligonucleotides such as those containing phosphotriester and methylphosphonate linkages also contain a substitution of one of the oxygen atoms bonded to phosphorous and thus exist as diastereomers.

Chemical synthesis of phosphorothioate-containing 10 oligonucleotides generally lacks stereoselectivity and results in the formation of a product which is a heterogeneous mixture of two different chiral species. Attempts to stereochemically control the synthesis of chirally pure 15 oligonucleotides have met with mixed success (Stec, et al., *Nucleic Acids Research*, 19(21): 5883-5888 (1991)). Cook (U.S. Pat. No. 5,212,295) has described the chemical synthesis of modified oligonucleotides with greater than 75% chiral purity. In comparison, enzymatic synthesis of 20 phosphorothioate-containing oligonucleotides can be used to produce chirally pure product, since several polymerases form only phosphorothioate linkages having the Rp orientation (Eckstein, *Ann. Rev. Biochem.* 54: 367-402 (1985)).

The enzymatic synthesis of other modified 25 oligonucleotides is also well known in the art. Methylphosphonate-containing oligonucleotides can be produced enzymatically using DNA polymerases α and ε from human placenta, DNA polymerase β from rat liver, and reverse transcriptases from HIV and avian myeloblastosis 30 virus (Dyatkina, et al., *Nucleic Acids Research Symposium Series* 24: 238 (1991)).

The economical enzymatic synthesis of any oligonucleotide, whether modified or not, depends on the ability to efficiently utilize the components of the 35 synthesis reaction to form a product which is sufficiently pure for its intended use. In some instances, it is desirable to use synthesis components which are capable of

functioning repeatedly and are thus "reusable". For example, Richards et al. (PCT WO 92/05287) describes the use of reusable synthesis templates which function repeatedly in the same synthesis reaction. In other 5 instances, it may be desirable to use synthesis components which function only once in a synthesis reaction and are thereafter degraded or rendered nonfunctioning. Walder, et al. (European Patent Application 496,483 A2) describe the use of RNA-containing primers that are cleaved in 10 order to prevent the formation of undesired amplification products in subsequent synthesis reactions.

Even though many of the prior art methods are suitable for use in the enzymatic synthesis of oligonucleotides, large scale synthesis of chirally pure 15 oligonucleotides has yet to be optimized. It is therefore an object of the present invention to provide for the economical synthesis of oligonucleotides which are chirally pure.

The present invention describes a convenient and 20 economical method of enzymatically synthesizing oligonucleotides. By utilizing 3'-ribonucleotide primers, separation of enzymatically synthesized oligonucleotides from primers is greatly facilitated and allows for regeneration of functional primers which can then be used 25 in subsequent synthesis reactions.

Regardless of whether phosphorothioate-containing oligonucleotides are chemically or enzymatically synthesized, their resistance to hydrolysis makes them difficult to cleave as is sometimes desirable during 30 synthesis and/or purification. Most studies involving phosphorothioate-containing oligonucleotides and restriction endonucleases have centered on the design of oligonucleotides which are protected from cleavage (Nakamaye, et al., Nucleic Acid Research 14 (24) : 9679- 35 9699 (1986); Richards et al., *supra*; and Vosberg, et al., Journal of Biol. Chem., 257(11) : 6595-6599 (1982)).

Accordingly, the present invention describes a convenient and economical method of enzymatically synthesizing chirally pure oligonucleotides which utilizes templates with repeating sequences that can optionally be 5 digested after synthesis, i.e. "digestible templates." Each of these templates can direct the synthesis of multiple copies of a given oligonucleotide. Further, restriction endonuclease recognition sites can be incorporated into the synthesis products. After 10 enzymatically synthesizing the desired oligonucleotide product, template digestion and/or product digestion greatly facilitates separation and purification of the synthesized oligonucleotides.

Alternatively 3'-ribonucleotide primers can be 15 utilized for the synthesis of the oligonucleotides. This greatly facilitates separation of the enzymatically synthesized oligonucleotides from the primers and allows for regeneration of functional primers which can then be used in subsequent synthesis reactions.

20 Additionally, the present invention involves the identification of several restriction endonuclease recognition sequences ("restriction sequences") which are capable of being recognized and cleaved by restriction endonucleases, even when present in fully 25 phosphorothioated oligonucleotides. This enables the enzymatic synthesis of partially or fully phosphorothioated oligonucleotides with the above identified benefits of separation and purification when these restriction sequences are incorporated into the 30 enzymatic products. In addition, the present invention provides a general method of cleaving phosphorothioate oligonucleotides which is useful in other basic molecular biology procedures.

None of the references herein are admitted to be 35 prior art.

Summary of the Invention

The present invention provides a method of synthesizing oligonucleotides by using optionally digestible templates which are capable of directing the synthesis of an oligonucleotide product which can optionally be cleaved into two or more individual oligonucleotides. Further, the template can optionally be cleaved and reused in subsequent synthesis reactions. The method of the present invention generally includes the steps of: (a) providing a nucleic acid template, the template comprising a primer binding region and an oligonucleotide complementary region, wherein the oligonucleotide complementary region optionally comprises more than one subregion such that each template is used to direct the synthesis of two or more oligonucleotides having the same or different lengths and/or sequences; (b) contacting the template with a nucleic acid primer able to hybridize to the template to form a template-primer hybrid; (c) incubating the template-primer hybrid in the presence of at least one DNA polymerase under conditions in which DNA synthesis occurs to form a primer extension product; (d) cleaving the primer extension product to separate the primer from the oligonucleotides and the oligonucleotides from each other; (e) optionally repeating steps (b) and (c) at least once with the primer from step (d); and (f) optionally before, simultaneous with or subsequent to step (d) or (e), digesting the template.

The template can be either DNA or RNA, but is preferably RNA. Each template is composed of two regions: a primer binding region (or a self-complementary region in the case of a self-priming template), and an oligonucleotide complementary region. The oligonucleotide complementary region may contain two or more subregions, each of which can have the same or a different nucleic acid sequence, such that each subregion directs the synthesis of an individual oligonucleotide. In this manner, oligonucleotides having the same or different

lengths and/or sequences may be formed from the same template.

The primers form template-primer hybrids when hybridized to the template. Alternatively, a separate primer need not be supplied if a self-priming template is used and the 3'-terminus of the self-priming template serves as the primer.

Primers which are particularly useful either contain or form at least one cleavable nucleotide linkage which, when incorporated into the primer extension product, can serve as a convenient cleavage site for separation of the primer from the oligonucleotide or oligonucleotides (i.e. the "oligonucleotide product").

The template-primer hybrid, or the self-priming template, directs the synthesis of a primer extension product via sequential addition of nucleotides or modified nucleotides. The use of modified nucleotides is preferred for formation of modified oligonucleotides which are nuclease-resistant.

Cleavage of the primer extension product to separate the primer from the oligonucleotide product can be facilitated by using a primer which contains or forms at least one cleavable internucleotide linkage. Such a primer is, for example, a 3'-ribonucleotide primer which forms a cleavable linkage which is susceptible to alkaline hydrolysis and/or RNase cleavage.

The 3' -ribonucleotide primers consist of DNA with at least one ribonucleotide residue or near their 3' -terminus. When used as primers in the enzymatic synthesis of oligonucleotides, they form at least one cleavable nucleotide linkage between the primer and the synthesis product which serves as a convenient cleavage site for separation of the primer from the synthesis product. Preferably, the 3' -ribonucleotide primers contain a single ribonucleotide at the 3' terminus. After cleavage the 3' -OH terminus of the primer can be regenerated using

phosphatase, and the primer can be used in a subsequent synthesis reaction.

Alternatively, when a primer is used which is DNA with a single deoxyuridine residue at its 3'-terminus, 5 the primer extension product can be cleaved by excising the deoxyuridine residue using a combination of DNA glycosylase, AP-endonuclease and exonuclease. Cleavage can also be facilitated by using a template which directs 10 synthesis of a primer extension product containing at least one restriction endonuclease recognition sequence, i.e., a "restriction sequence."

Additionally, when the template's oligonucleotide complementary region contains two or more subregions which are each designed to direct the synthesis of an individual 15 oligonucleotide, incorporation of restriction sequences into the primer extension product is used to position cleavage sites in the oligonucleotide product to facilitate separation of the individual oligonucleotides. Cleavage to separate the individual oligonucleotides from 20 each other can then be accomplished using the appropriate restriction endonuclease.

The oligonucleotides of the invention can be synthesized using phosphorothioate linkages. One aspect of the present invention is based on the discovery of 25 several restriction endonuclease recognition sequences ("restriction sequences") which are capable of being recognized and cleaved by certain restriction endonucleases even when present in fully phosphorothioated oligonucleotides ("phosphorothioate oligonucleotides".) 30 Accordingly, the present invention involves a method of cleaving phosphorothioate oligonucleotides containing restriction sequences at predetermined cleavage sites using particular restriction endonucleases. In particular it relates to the use of the following restriction 35 sequences and restriction endonuclease combinations: 5' -GGCC-3' and Hae III; 5' -GCGC-3' and HinP I; 5' -CCNGG-3' and ScrF I; and 5' -TCGA-3' and Taq[®] I.

When the primer extension product is a partially or fully phosphorothioated oligonucleotide, preferably at least one of these restriction sequences is incorporated in the extension product to create a cleavage site.

5 When digestion of the template is used to separate the primer extension product from the template, cleavage to separate the primer from the oligonucleotide product and, if necessary, the individual oligonucleotides from each other, can take place before, during or after 10 template digestion. Digestion of an RNA template can be accomplished via alkaline hydrolysis and/or an appropriate Rnase. Digestion of a DNA template can be accomplished using an appropriate DNase.

15 Brief Description of the Drawings

As used in the Figures described below, the abbreviations will have the following meaning:

20 pbr = primer binding region
ocr = oligonucleotide complementary region
sr = subregion
cs = cleavage site
scr = self-complementary region
R = ribonucleotide

25 Figure 1 illustrates several different template structures, each containing a primer binding region and an oligonucleotide complementary region.

30 Figure 2 illustrates several different template structures, each containing a primer binding region, and an oligonucleotide complementary region which consists of three separate subregions.

Figure 3 illustrates the use of a template precursor which is cleaved to form two separate templates.

Figure 4 illustrates the enzymatic synthesis of an oligonucleotide using a self-priming template.

35 Figure 5 illustrates the enzymatic synthesis of an oligonucleotide using a combined primer/template.

Figure 6 illustrates the enzymatic synthesis of an oligonucleotide using a 3'-ribonucleotide primer.

Figure 7 illustrates the enzymatic synthesis of two or more oligonucleotides from a single template using a 5 primer-extension product containing more than one type of cleavage site, one being the phosphate linkage 3' to a ribonucleotide residue which was introduced into the primer extension product by using a 3'-ribonucleotide primer, and the other being a restriction endonuclease 10 recognition sequence.

Description of the Preferred Embodiments

In order to more clearly describe the subject matter of the present invention, certain terms used herein shall 15 be defined as follows unless otherwise indicated:

Chirally pure: "Chirally pure", when used to refer to a phosphorothioate-containing oligonucleotide, means that the oligonucleotide contains only Rp or Sp diastereomers.

Cleavage Site: "Cleavage site" means a location in 20 a nucleic acid that is susceptible to hydrolysis of at least one native or modified phosphodiester bond in the sugar-phosphate backbone of the nucleic acid. When used to refer to a restriction endonuclease recognition sequence, the term "cleavage site" means the cleavable 25 linkage (denoted as "/") in a sequence of nucleotides which are specifically recognized by a restriction endonuclease which binds to the sequence to effectuate cleavage. For example, the sequence GGCC is recognized by Hae III and cleavage occurs at GG/CC. "Cleavage site", as used 30 herein, can also mean the linkage 3' to a ribonucleotide residue, which is susceptible to cleavage by an agent such as RNase or alkali.

Cleave: "Cleave" means to cause a break in the sugar-phosphate backbone of an oligonucleotide using an 35 endonuclease or other cutting agent.

Complementary: "Complementary", when used to refer to a nucleic acid, means a nucleic acid of one polarity

containing a sequence of nucleotides whose bases pair with the nucleotide bases of another nucleic acid of opposite polarity, i.e. adenine ("A") pairs with thymine ("T") or uracil ("U"), and guanine ("G") pairs with cytosine ("C").

5 For example, a nucleic acid having the sequence GCAU in the 5' to 3' direction is "complementary" to a nucleic acid having the sequence CGTA in the 3' to 5' direction. Use of the term complementary herein is intended to include those nucleic acids which are substantially 10 complementary. Complementary nucleic acids can also be referred to as one being the plus ("(+)") or "sense" strand and the other being the minus ("(-)") or "antisense" strand.

15 Diastereomer: "Diastereomer" means a chiral compound that can exist as two different chiral species which, in the case of phosphorothioate-containing oligonucleotides, depends on the orientation of sulfur in relation to the chiral phosphorous. The two possible orientations are *Rp* and *Sp*, thus the chiral species are referred to as being 20 *Rp* or *Sp* diastereomers.

Digestion: "Digestion" means the degradation of a nucleic acid into its individual nucleotides (complete digestion) or into short segments (partial digestion).

25 dNTP: "dNTP" means a deoxynucleoside triphosphate, wherein N refers to the nucleotide bases, i.e. dATP means deoxyadenosine triphosphate, dCTP means deoxycytosine triphosphate, etc. The term "dNTP", or "nucleotide", is intended to include an unmodified deoxynucleoside triphosphate, as well as a deoxynucleoside triphosphate 30 with a modified α linkage, such as deoxynucleoside triphosphorothioate and deoxynucleoside methylphosphonate.

35 dNTP α S: "dNTP α S" means a deoxynucleoside triphosphates having a sulfur atom substituted for oxygen at the alpha phosphorous position wherein N is defined as described for dNTP.

Hairpin: "Hairpin" means the looped self-hybridized structure that a self-priming template takes when the two

intra-complementary regions, which are separated by a non-complementary region that becomes the "loop", form a duplex. See Figure 4.

5 Hybridization: "Hybridization" means the formation of a stable duplex between nucleotide sequences that are substantially complementary.

10 Modified: "Modified", when used to refer to a nucleic acid, means a nucleic acid in which any of the natural structures have been altered. These include the native phosphodiester linkages (also referred to herein as simply "phosphodiester linkages"), the sugars (ribose in the case of RNA or deoxyribose in the case of DNA) and/or the purine or pyrimidine bases. Modified phosphodiester linkages include phosphorothioates, phosphotriesters, 15 methylphosphonates and phosphorodithioates.

20 Nucleic Acid Sequence: "Nucleic acid sequence", or "sequence", means both a nucleic acid having a particular sequence of nucleotides, and also the sequence or order of nucleotides present in a particular nucleic acid. Which of these two meanings applies will be apparent from the context in which this term is used.

25 Oligonucleotide: "Oligonucleotide" means a relatively short segment of a nucleic acid polymer. Although a limitation to any precise length is not intended, oligonucleotides are generally between 8 to 100 nucleotides in length.

30 Polarity: "Polarity" means the orientation of a nucleic acid polymer which is created when the C3 position of one deoxyribose (or ribose) moiety is linked together with the C5 of the adjacent deoxyribose (or ribose) moiety via a native or modified phosphodiester linkage. Polarity is created by the sequence of bases relative to the 5' and 3' ends. Two complementary strands are of "opposite polarity" when the sequence of bases read from the 5' to 3' direction of one strand and the sequence of bases read from the 3' to 5' direction of the other give

corresponding Watson and Crick base pairs at each position.

5 Phosphorothioate oligonucleotide: "Phosphorothioate oligonucleotide" means an oligonucleotide having all phosphorothioate linkages (also referred to as a "fully phosphorothioated oligonucleotide").

10 Phosphorothioate-containing oligonucleotide: "Phosphorothioate-containing oligonucleotide" means an oligonucleotide having at least one but less than all phosphorothioate linkages (also referred to as a "partially phosphorothioated oligonucleotide").

15 Polymerase: "Polymerase" means an enzyme which is capable of catalyzing the synthesis of a complementary copy of a nucleic acid template, which in the case of a DNA polymerase is brought about by the sequential addition of deoxynucleotides to a primer.

20 Primer: "Primer" means an oligonucleotide that is complementary to a template that hybridizes with the template to give a template-primer hybrid for initiation of synthesis by a DNA polymerase, such as reverse transcriptase or bacteriophage T4 DNA polymerase, and which is extended by the sequential addition of covalently bonded nucleotides linked to its 3' end that are complementary to the template. The result is the 25 formation of a primer extension product.

30 RNase H: "RNase H" means an enzyme that degrades the RNA strand of an RNA:DNA duplex.

35 Self-priming template: "Self-priming template" means a template which is capable of initiating synthesis by a polymerase without the addition of a separate primer. The 3'-terminus of a self-priming template serves as the primer.

Self-Priming Template Extension Product: "Self-priming template extension product" means the product which is formed during oligonucleotide synthesis using a self-priming template. As used herein, a self-priming template extension product is a type of primer extension

product to which the template remains covalently attached after synthesis.

5 Substantially Complementary: "Substantially Complementary", when used to refer to a nucleic acid, means having a sequence such that not all of the nucleotides exhibit base pairing with the nucleotides of another nucleic acid, but the two nucleic acids are nonetheless capable of forming a stable hybrid under specified conditions.

10 Template: "Template" means a nucleic acid molecule that is able to be copied by a polymerase, and which has a sequence of nucleotides which will provide the pattern and serve as substrate for producing a desired oligonucleotide. In order to serve as such, the template 15 must contain a sequence which is capable of hybridizing with a primer (a "primer binding region"). A self-priming template must contain a sequence which is capable of forming a hairpin structure (a "self-complementary region").

20 Template precursor: "Template precursor" means an oligonucleotide which contains at least one copy of the template nucleic acid sequence and can be cleaved to produce at least one template nucleic acid.

25 Template-primer hybrid: "Template-primer hybrid" means a partially double-stranded nucleic acid which is formed when a template and a primer hybridize.

30 Oligonucleotides have many different uses in biomedical science. To name a few, they can be used as labelled probes for detection of specific nucleic acid sequences in diagnostic assays (Kohne et al., U.S. Patent No.s 4,851,330 and 5,288,611); they can be used to promote formation of regions in an RNA target which are accessible to hybridization of labelled probes (See Hogan et al., U.S. Patent No. 5,030,557); they can be used as 35 investigational tools for the sequencing of DNA (Biggin et al., P.N.A.S. 80: 3936-3965 (1983); and, especially in the case of modified oligonucleotides, they can be used in

5 biological systems. Because of the ability of certain modified nucleic acids to resist degradation by nucleases, they are much more stable in such systems than their unmodified (native) phosphodiester counterparts. This makes them ideal for use *in vivo* as antisense therapeutic agents.

10 "Antisense" refers to the use of oligonucleotides as regulators of gene function. An antisense oligonucleotide, i.e. an oligonucleotide having a nucleic acid sequence which is complementary to that of the "sense" nucleic acid to which it is targeted, can function in many different ways to modulate gene function. When the targeted nucleic acid is messenger RNA ("mRNA"), it may function by preventing translation of the mRNA into protein or inhibiting binding of ribosomes. When the targeted nucleic acid is DNA, it may prevent transcription into mRNA.

15 The use of phosphorothioate-containing oligonucleotides in the field of antisense therapeutics is now widespread. Examples of a few of the applications are: the treatment of acute myeloblastic leukemia (Bergot, et al., Nucleic Acids Symposium Series No. 29, pg. 57 (1993)); the inhibition of HIV replication (Matsukura et al., Gene 72: 343-347 (1988)); and the inhibition of influenza virus replication (Leiter et al., P.N.A.S. 87: 3430-3434 (1990) and Cohen et al., U.S. Patent No.s 5,264,423; 5,276,019; and 5,286,717).

20 Oligonucleotides which are useful for particular purposes can be "designed" to hybridize with selected portions of a target sequence and, by varying such things as length and target binding region, their suitability for certain purposes can be maximized. For example, if the desired oligonucleotide product is an antisense therapeutic to be used in targeting the protein coding region of mRNA, an oligonucleotide might be chosen which would be complementary to an accessible region of the mRNA sequence, i.e. one expected not to contain secondary

structure, with sufficient length and complementarity to a unique sequence so as to not exhibit cross-reactivity with non-targeted nucleic acids.

5 Although appropriate oligonucleotide length depends entirely on the particular use for which the oligonucleotide is designed, certain generalizations are possible. If the oligonucleotide is to be used as a linker in cloning, it will preferably be between about 6 and 60 nucleotides in length. If it is to be used as a 10 sequence-specific hybridization probe, it will preferably be between 12 and 60 nucleotides in length. If it is to be used as a polymerase chain reaction ("PCR") primer, it will preferably be between about 8 and 35 bases. If it is to be used as a ligase chain reaction ("LCR") primer, it 15 will preferably be between about 8 and 35 nucleotides in length. If it is to be used as an antisense therapeutic agent, it will preferably be between about 12 and 50, and more preferably between about 15 and 30 nucleotides in length.

20 The present invention is particularly well-suited for use in enzymatically synthesizing phosphorothioate oligonucleotides which are chirally pure. It generally involves the use of templates and primers to form template-primer hybrids (or the use of self-priming 25 templates to form hairpins), the synthesis of primer extension products, and the cleavage and separation of the desired individual oligonucleotides. Each of these aspects are more fully described below.

30 The Template

35 The template can be either DNA or RNA, or modified DNA or RNA, but is preferably unmodified RNA to facilitate digestion. Templates having a specific nucleic acid sequence can be prepared using any known chemical or enzymatic methods. In addition, templates can be prepared using any known recombination or cloning methods, such as with plasmids, M13 DNA, etc. Chemical synthesis can be

conveniently performed according to the method described by Stec et al. (J. Am. Chem. Soc. 106: 6077-6079 (1984)) using the phosphoroamidite method and an automated synthesizer, such as Model 380-B (Applied Biosystems, Inc., Foster City, California).

Particularly useful methods for synthesizing templates are based on enzymatic amplification technologies for producing multiple copies from as few as a single copy of a nucleic acid. The following references, which are incorporated herein in their entirety, are representative of several different amplification procedures which can be employed for production of template. PCR for the production of DNA is described by Mullis, et al. (See U.S. Patent No.s 4,683,195; 4,683,202; and 4,800,159, and Methods in Enzymology, Volume 155, 1987, pp. 335-350.) A Q β replicase-based amplification system for producing RNA is described by Kramer, et al., in U.S. Patent No. 4,786,600.

Because single-stranded template preparation lacking complementary strands are ideal, preferred amplification procedures utilize transcription-based amplification systems, which produce multiple copies of single-stranded RNA from double-stranded DNA. (See Burg, et al., WO 89/01050 and Gingeras, et al., WO 88/10315.) Still other transcription-based amplification methods are described by Kacian, et al. (WO 91/01384 and WO 93/22461) and McDonough, et al., (WO 94/03472). PCR has also been used to produce single-stranded RNA from double stranded DNA from which RNA is synthesized in vitro using DNA-directed RNA polymerase. (See Murakawa, et al., DNA 7:287-295 (1988)).

The nucleic acid sequence of a template will necessarily have at least two nucleic acid subsequences; one of which is complementary to the primer, i.e. the "primer binding region", and another of which is complementary to the oligonucleotide product to be synthesized, i.e. the "oligonucleotide complementary region." In addition, the

template can be in the form of a plasmid, or a PCR product (after denaturation and strand separation), or restriction fragments or linearized versions thereof. For examples of different template structures, see Figure 1.

5 In order to use a single template for the production of more than one oligonucleotide, a template is synthesized which contains an oligonucleotide complementary region having more than one subregion, such that each subregion is complementary to and capable of directing the 10 synthesis of an individual oligonucleotide. See Figure 2. Using such a template, the oligonucleotide complementary region is complementary to and directs the synthesis of an "oligonucleotide product", which can then be cleaved after synthesis to separate the individual oligonucleotides.

15 A template with more than one such subregion must also be designed to facilitate separation of the individual oligonucleotides from each other after synthesis. This can be accomplished by incorporating restriction sequences into the primer extension product which are 20 specifically positioned to allow for cleavage to separate the individual oligonucleotides. (See Cleavage of the Primer-Extension Product below for a more complete description of cleavage to separate individual oligonucleotides.)

25 The individual oligonucleotides synthesized in this manner may have the same or different sequences, as well as the same or different lengths. This method is very useful when pairs of oligonucleotides which do not require further separation are to be used for a particular application.

30 The template can be formed such that it is ready for use in the synthesis of oligonucleotides, or it can be formed as a template precursor which can then be converted to a usable template by cleavage with an endonuclease or 35 other such cleavage mechanism. (See Cleavage of the Primer-Extension Product below for a complete description of cleavage mechanisms.) See Figure 3.

Additionally, templates can be self-priming, i.e. capable of initiating synthesis without the need for a separate primer. Instead of a primer binding region, a self-priming template has a "self-priming region." This 5 self-priming region contains two intra-complementary regions separated by several, usually 3 to 5, nucleotides. The intra-complementary regions form a duplex, and the several nucleotides separating the intra-complementary regions form a loop. The 3' terminal base must be paired, 10 and the region of complementarity must be sufficient to allow priming to occur. The resultant structure is referred to as a "hairpin". (Dattagupta, European Patent Application No. 427,073A2.) See Figure 4. As shown, the 15 3'-terminus of the self-priming template serves as the primer.

It is also possible to design templates with primer complementary regions such that the primer complementary region of one template molecule will hybridize with the primer complementary region of another template molecule 20 to form a duplexed primer complementary region. In this manner, one template serves as the primer for another, thus eliminating the need for a separate primer. These templates can be referred to as "primer/templates", since 25 they serve both functions. See Figure 5. As shown, using DNA primer/templates with a single 3'-ribonucleotide, the primer/template can be separated from the oligonucleotide product via alkaline hydrolysis and/or RNase.

The Primer

30 The primer can be synthesized using any of the aforementioned methods for synthesizing template. The primer can be either DNA or RNA, or a modified DNA or RNA. A particularly useful primer is a 3'-ribonucleotide primer which consists of DNA with several, preferably 1 to 4, 35 ribonucleotides at or near (i.e. within 1 to 3 nucleotides of) its 3'-terminus. Preferably, the primer is a 3'-ribonucleotide primer consisting of DNA with a single

ribonucleotide residue at its 3'-terminus. This type of primer has been utilized to prevent contamination during PCR (Walder et al., European Patent Application 496,483 A2). As used herein, 3'-ribonucleotide primers provide 5 a convenient cleavage site for separation of the primer from the oligonucleotide product, since the internucleotide linkage which is 3' to a ribonucleotide residue is cleavable by chemical or enzymatic means.

The 3'-ribonucleotide primers are preferred, because 10 they are capable of retaining their function after cleavage of the primer extension product to separate the primer from the oligonucleotide product. A primer which "retains its function" after cleavage is one which is capable of remaining hybridized to the same template, or 15 hybridizing to a different template, to initiate a subsequent synthesis reaction.

Ribonucleotide-containing primers can be prepared using known methods of oligonucleotide synthesis. For example, see Walder, et al., *supra*. When a ribonucleotide-containing primer is used with an RNA template, 20 cleavage of the primer extension product and digestion of the template can be accomplished simultaneously. See Figure 6. See below for a more complete description of primer extension product cleavage and template digestion.

Another useful primer consists of an oligonucleotide 25 which contains at least one deoxyuridine at the 3'-terminus. After synthesis of the primer extension product, the deoxyuridine residue can be excised by the combined action of a DNA glycosylase, followed by cleavage 30 of the phosphate bond by an apurine/apyrimidine endonuclease (AP-endonuclease), and removal of the resultant exposed baseless sugar by an exonuclease. (See McGilvery, et al., *Biochemistry: A functional Approach*, W.B. Saunders Co., Philadelphia, Pennsylvania, 125-126 (1983).)

Formation of the Template-Primer Hybrid

Prior to oligonucleotide synthesis, a primer must be hybridized to the template. A template and primer combination should be used such that the primer binds to the primer binding region and not to any other region of the template. Thus, primers should be long enough and sufficiently complementary to the primer complementary region to form a stable duplex with it. The duplex thus formed allows the 3'-OH terminus of the primer to function as an initiation site for synthesis.

The primer and the template can be prehybridized prior to use, but are preferably added sequentially or simultaneously to the synthesis reaction mixture prior to addition of the polymerase. The hybridization conditions necessary to cause specific duplex formation between the primer and the template will most importantly depend on the specificity of the primer for the template's primer binding region, but will also depend to some degree on the heterogeneity of the nucleic acids present. The hybridization conditions must also be compatible with the polymerase enzyme being able to perform efficient and accurate synthesis. If chemically produced template is used wherein contamination by exogenous nucleic acids would be expected to be minimal, a wide range of hybridization conditions can be used to selectively hybridize the primer to the template. When the template is produced enzymatically in the presence of contaminating nucleic acids, hybridization conditions must be more stringent in order for selective hybridization of the primer and the template to occur. Stringency can be increased by any known method, such as lowering ionic strength, increasing washing temperatures, and/or using a denaturing agent.

Formation of the Primer Extension Product

The 3'-OH terminus of the primer in the primer-template hybrid serves as the initiation site for synthesis via sequential addition of dNTPs in the 5' to 3' direction. Alternatively, when a self-priming template is utilized, it is the 3'-OH terminus of the template's self-complementary region which serves as the initiation site for synthesis. The mixture of nucleotides to be used in the synthesis may contain either all unmodified, all modified, or both unmodified and modified dNTPs in appropriate ratios, such that a desired amount of incorporation of the modified dNTP is achieved. If a fully phosphorothioated oligonucleotide is to be synthesized, only dNTP α Ss will be used. The modified dNTPs used may be the same or different, but are preferably the same (i.e. all methylphosphonates, all phosphorothioates, etc.) In addition, the mixture of dNTPs which are available for synthesis must contain all of the nucleotides necessary for formation of the primer extension product.

The choice of polymerase will depend on the template and the substrates used, and any requirements for specific reaction conditions (e.g. thermostable polymerases for high temperature reactions). Polymerases suitable for use with a variety of templates and substrates are well known in the art.

DNA-dependent DNA polymerases synthesize a complementary DNA copy of a DNA template. Examples of suitable DNA-dependent DNA polymerases include, but are not limited to: DNA polymerase I (Burgess, et al., *Journal of Biol. Chem.* 254: 6889-6893 (1979)); T4 polymerase (Romaniuk, et al., *Journal of Biol. Chem.* 257: 7684-7688 (1982)); and T7 polymerase (Brody, et al., *Biochemistry* 21: 2570 (1982)). Each of these polymerases can also be used to synthesize phosphorothioate oligonucleotides. All known DNA-dependent DNA polymerases require a complementary primer to initiate synthesis. Generally, the primer may be RNA or

DNA, or a copolymer of RNA and DNA, to initiate synthesis. It is known that under suitable conditions certain DNA-dependent DNA polymerases may also synthesize a complementary DNA copy of an RNA template.

5 RNA-dependent DNA polymerases, also called reverse transcriptases, synthesize a complementary DNA copy of an RNA template. Examples of suitable RNA-dependent DNA polymerases include, but are not limited to avian myeloblastosis virus reverse transcriptase (Bartlett, et al., Journal of Biol. Chem. 257 (15): 8879-8854 (1982)). This enzyme, as well as other reverse transcriptases known in the art, is also capable of being used to synthesize phosphorothioate oligonucleotides. All known reverse transcriptases also have the ability to make a complementary DNA copy of a DNA template and are thus both RNA- and DNA-dependent DNA polymerases.

Cleavage of the Primer Extension Product

20 The primer extension product will necessarily have at least one cleavage site, and may have several equivalent or different cleavage sites. One cleavage site is necessary to separate the oligonucleotide product from the primer and, if the template's oligonucleotide complementary region consist of two or more subregions 25 each having a sequence complementary to an individual oligonucleotide, the oligonucleotide product must contain cleavage sites for separation of the individual oligonucleotides.

30 When using a template to synthesize more than one individual oligonucleotide, it may be desirable to form a primer extension product with more than one type of cleavage site, one of which may be the phosphate linkage adjacent to a ribonucleotide residue which was formed by using a 3'-ribonucleotide primer, and the other of which 35 may be a restriction endonuclease recognition sequence. In this manner, the primer extension product can be cleaved once to separate the primer, and then cleaved

again (before or after purification) to separate the individual oligonucleotides from each other. See Figure 7.

Different restriction sites can be incorporated into 5 the primer extension product, each of which is recognized by a different restriction endonuclease, such as those identified in Example II below. An important aspect of the present invention is the discovery of several previously unknown restriction endonuclease/restriction 10 sequence combinations which result in the cleavage of phosphorothioate oligonucleotides.

That these restriction sequences were capable of being recognized in phosphorothioate oligonucleotides and cleaved was an unexpected finding. Taylor, et al. 15 (Nucleic Acids Research, 13(24): 8749-8764 (1985)) have reported that several restriction endonucleases, such as Alu I, are capable of cleaving partially phosphorothioated oligonucleotides. It was expected that there would be a correlation between the ability of restriction 20 endonucleases to cleave partially phosphorothioated oligonucleotides and their ability to cleave fully phosphorothioated oligonucleotides. However, this was found not to be the case in all instances, and the efficiency of a restriction endonuclease to cleave fully 25 phosphorothioated oligonucleotides could not be predicted based on previous results with partially phosphorothioated oligonucleotides. See Examples I to III.

In addition to the use of site-specific restriction endonucleases, if a 3'-ribonucleotide primer was used in conjunction with a DNA template, cleavage to separate the 30 primer and the oligonucleotide product can be accomplished with alkaline hydrolysis, or by the use of an endonuclease, such as RNase.

RNase H's may contain either or both endonuclease or 35 exonuclease activity. Avian myeloblastosis virus and Moloney murine leukemia virus reverse transcriptases contain an RNase H activity in addition to their

polymerase activity. However, some cloned reverse transcriptases lack RNase H activity. There are also sources of RNase H available without an associated polymerase activity. Although the cleavage site of most RNase H's requires the presence of more than one ribonucleotide residue, RNase H's which are capable of cleaving a DNA strand containing a single internal ribonucleotide residue have been reported. (See Walder, et al., *supra*).

10 Cleavage of a primer extension product which is formed using a 3'-ribonucleotide primer occurs in the phosphate linkage(s) which is/are in the 3' direction from the ribonucleotide residue(s). Cleavage by alkali causes the formation of a mixture of 2'-, 3'- and 2',3'-cyclic 15 phosphate ribonucleotides, which can then be "regenerated" by converting it back to a 3'-OH by alkaline phosphatase. Preferably, an RNase is used which results in reformation of a primer with a 3'-OH terminus. When the 3'-ribonucleotide primer consists of DNA with a single ribonucleotide residue at the 3' terminus, the regenerated or reformed primer will be identical to the original primer. Such primers are particularly preferred for this reason.

20 If a deoxyuridine-containing primer is used, cleavage can be accomplished by hydrolysis with a DNA glycosylase, 25 followed by cleavage of the phosphate bond by an apurinic/apyrimidinic-endonuclease ("AP-endonuclease") and removal of the baseless sugar by an exonuclease. (See McGilvery, et al., *Biochemistry: A functional Approach*, *supra*.)

25 In instances where the primer and the oligonucleotide 30 to be synthesized are both the same type of nucleic acid, for example both unmodified RNA or DNA, it is also possible for some of the nucleotides of the primer to be incorporated into the oligonucleotide product after cleavage of the primer extension product. In this 35 situation, cleavage of the primer extension product occurs in the 5' direction from the original 3'- terminus of the primer, and one or more of the primer's nucleotides become

incorporated into the 5' end of the oligonucleotide. Alternatively, it is possible for cleavage of the primer extension product to occur in the 3' direction from the original 3'-terminus of the primer. However, in both 5 instances, the primer will not be able to be used in subsequent synthesis reactions.

In instances where a DNA primer/template with a single 3'-ribonucleotide is used, cleavage at the ribonucleotide residue as described above, followed by 10 separation and purification of the oligonucleotide product, can result in a fully regenerated and reusable primer/template.

Digestion of the Template

15 The template is preferably capable of being digested after formation of the primer extension product. Using nucleases which will only recognize the double-stranded product formed after synthesis of the oligonucleotide, it is possible to digest the template only after formation of 20 the primer extension product without digesting single-stranded template that has not yet directed the synthesis of a primer extension product. Digestion of the template can occur either before, simultaneously with or after cleavage of the primer extension product. Digestion of 25 the template can serve two useful purposes; (1) synthesis reaction components can easily be recovered and reused; and (2) digestion leaves the oligonucleotide and the primer (or in the case of pre-cleavage digestion, the primer-extension product) in single-stranded form thus 30 facilitating purification and/or separation from the synthesis reaction mixture.

If the template is DNA, digestion can be accomplished using a DNase. The oligonucleotide product can be protected from nuclease digestion by virtue of the incorporation 35 of modified linkages during synthesis. If a modified primer is also used which is not digested by the DNase, the template can be selectively digested in the presence

of primer, oligonucleotide and/or primer-extension product.

Preferably, the template is RNA, in which case digestion can easily be accomplished using alkaline hydrolysis and/or a suitable RNase.

Example I

Determination of Restriction Endonuclease Effectiveness

The primer extension product can be cleaved with restriction endonucleases, provided that the template is designed to direct the synthesis of a primer extension product that contains a sequence which can be recognized by such an enzyme. Many restriction endonuclease recognition sequences are known in the art. (See *The Biochemistry of the Nucleic Acids: Chapter 4, Degradation and Modification of Nucleic Acids, supra.*)

Due to the resistance of many modified oligonucleotides to be recognized and thus cleaved by restriction endonucleases, it is necessary to prescreen restriction endonucleases prior to use in oligonucleotide synthesis for their ability to cleave a nucleic acid which contains the same modifications which are intended to be incorporated into the primer extension product. A screening method for phosphorothioate oligonucleotides follows.

Screening for restriction endonuclease activity was carried out according to the method described by Taylor, et al. (Nucleic Acids Research, 13(24): 8749-8764 (1985)). The substrate utilized was double-stranded M13 DNA with a completely native phosphodiester-linked (+) strand and a completely phosphorothioate-linked (-) strand. A control was prepared which contained DNA with native phosphodiester linkages in both strands. Each restriction endonuclease was tested for its ability to digest the substrate by incubating twenty units of each restriction endonuclease with 0.5 µg M13 DNA for 1 hour at the

temperature and under the conditions described by the enzyme manufacturer for native phosphodiester DNA.

The restriction fragments which were formed using the assay substrate were compared to those formed using the 5 control, and results were scored accordingly. These results are reported in Table 1. A result reported as "++" indicates that complete cleavage of both the control and test substrates was obtained using the specified reaction conditions. A result reported as + indicates 10 that the restriction endonuclease was capable of cleaving the substrate, but less than complete cleavage occurred (i.e. "partial cleavage"). Even a result of only partial cleavage using this assay indicates that the restriction endonuclease should be suitable for use in the synthesis 15 of phosphorothioate-containing oligonucleotides, since the cleavage reaction can easily be further optimized. An "effective amount" of restriction endonuclease is the amount necessary to effect cleavage under specified conditions.

TABLE 1

RESTRICTION ENDONUCLEASE STUDY USING DOUBLE STRANDED
SUBSTRATE

5	Enzyme*	Results	Recognition Sequence
10	Alw N I	+	5' -CAGNNNN/CTG-3'
	Bsa J I	++	5' -C/CNNGG-3'
	Bsr I	++	5' -ACTGGN/-3'
	Bst N I	++	5' -CC/ (A, T) GG-3'
	Cla I	++	5' -AT/CGAT-3'
	Hae III	++	5' -GG/CC-3'
	Hin P I	++	5' -G/CGC-3'
	Msp I	+	5' -C/CGG-3'
	Mva I	++	5' -CC/ (A, T) GG-3'
	Scr F I	++	5' -CC/ (N) GG-3'
15	Taq α I	++	5' -T/CGA-3'

* All endonucleases except for Mva I were obtained from New England Biolabs, Inc., Beverly, MA. Mva I was obtained from Boehringer Mannheim, Indianapolis, IN.

N = A, T, C or G

/ = Location of cleavage

(A, T) = Either nucleotide

Example IIOptimization of Restriction Endonuclease Conditions

The effects of reaction conditions on cleavage efficiency of several endonucleases were studied using the procedure described in Example I. In particular, the effects of substituting sodium acetate for NaCl, and MnCl₂ for MgCl₂, were studied in order to find conditions which favor cleavage. A similar optimization could be performed with any restriction endonuclease by using the conditions reported as optimal by the enzyme manufacturer and varying the type and amount of cations, anions, buffers, etc.

Each of the NaCl and MgCl₂ concentrations were kept at standard concentrations while varying the concentration of the other. Optimums for each are reported in Table 2 below. Then, while using the optimum concentration of NaCl, a varying amount of MnCl₂ was added as a substitute for MgCl₂. Likewise, while using the optimum concentration MgCl₂, a varying amount of sodium acetate was added as a substitute for NaCl. The ability of MnCl₂ and sodium acetate to substitute for MgCl₂ and NaCl, respectively, are also reported in Table 2.

TABLE 2
EFFECTS OF DIFFERENT REACTION CONDITIONS

Enzyme	Conditions	NaCl, mM (0 to 400)	Sodium acetate, mM (0 to 400)	MgCl ₂ , mM (0.1 to 20)	MnCl ₂ , mM (0.1 to 10)
Hae III	Standard	50 mM	No effect	10 mM	No effect
	Optimum	0 mM		2-5 mM	
Taq ^a I	Standard	100 mM	No effect	10 mM	0.5-2 mM
	Optimum	50 mM		1-2 mM	
HinP I	Standard	50 mM	No effect	10 mM	2 mM
	Optimum	50 mM		10 mM	
BstN I	Standard	50 mM	No effect	10 mM	No effect
	Optimum	0 mM		No effect	
Mva I	Standard	25 mM	No effect	10 mM	No effect
	Optimum	100 mM		No effect	
ScrF I	Standard	100 mM	0-50 mM	5 mM	1 mM
	Optimum	0-50 mM		5-10 mM	

These results demonstrate that in most instances lowering the concentration of sodium chloride tended to increase the rate of phosphorothioate DNA cleavage. Similarly, lowering the magnesium chloride concentration was generally favorable to cleavage. Only in a few instances was any effect on cleavage observed by using MnCl₂ instead of MgCl₂, or sodium acetate instead of NaCl.

Example IIIRestriction Endonuclease Study using Single-Stranded Substrate

As shown in Figure 5, it is possible to use a ribose-containing primer in combination with an RNA template to synthesize multiple oligonucleotides from a single template. Using alkali and/or RNase to cleave the primer extension product at the location of the ribose residue and to digest the template, a single-stranded product remains which must be cleaved. In order to test the ability of the restriction endonucleases from Example 1 to cleave a single-stranded target, an oligonucleotide substrate was chemically synthesized which contained restriction endonuclease recognition sequences for all of the enzymes to be tested. The sequence of this oligonucleotide is given in SEQ. ID. NO. 1. Using the standard conditions reported in Example 2, several enzymes were tested for their ability to cleave the single-stranded oligonucleotide substrate. The results are given below in Table 3:

TABLE 3

RESTRICTION ENDONUCLEASE STUDY USING SINGLE-STRANDED
SUBSTRATE

5

Enzyme	Results
BstN I	-
Hae III	+
HinP I	+
Mva I	-
Scrf I	++
Taq ^a I	+

10

Results reported as "+" indicate partial cleavage of the oligonucleotide substrate. Results reported as "++" indicate complete cleavage of the oligonucleotide substrate. Results reported as "-" indicate no significant cleavage. Under these cleavage conditions, either result indicates that the particular restriction endonuclease tested would be suitable for use.

20

Example IV

Synthesis of an Oligonucleotide from an RNA Template

A. Preparation of Template

25

A template was chosen which would direct the synthesis of an antisense oligonucleotide which was complementary to the mRNA sequence given by SEQ. ID. NO. 2 encoding the HIV REV protein. (See Peterson, et al., Published PCT Application No. WO 95/03407.) Template was prepared by first chemically synthesizing an oligodeoxy-nucleotide having two subsequences; a T7 RNA polymerase self-complementary ("hairpin") promotor sequence (see SEQ. ID. NO. 3), and a sequence (see SEQ. ID. NO. 4) which was

30

complementary to the desired template. The sequence of this oligodeoxynucleotide is given by SEQ. ID No. 5.

The *in vitro* transcription from the oligodeoxynucleotide was carried out in a 20 ml reaction mixture containing 0.256 A₂₆₀ units of the oligodeoxynucleotide in 40 mM Tris (pH 8.0), 20 mM MgCl₂, 4 mM ATP, 4 mM GTP, 4 mM CTP, 4 mM UTP, 1 mM spermidine, 0.08% (w/v) polyethylene glycol (PEG) 8000, 0.01% (w/v) Triton X-100, 5 mM dithiothreitol (DTT), 50 µg/ml bovine serum albumin (BSA), 800 units of RNasin (Promega, Inc., Madison, WI), and 120,000 units of T7 RNA polymerase. The reaction mixture was incubated at 37°C for approximately four hours, or until formation of a magnesium pyrophosphate precipitate was observed.

15 The template thus formed had the sequence given by SEQ. ID. NO. 6, and consisted of two subsequences; the primer binding region (SEQ. ID. NO. 7) and the oligonucleotide complementary region (SEQ. ID. NO. 8).

20 The template was isolated by chromatography as follows: The magnesium pyrophosphate precipitate was dissolved by the addition of EDTA to a final concentration of 20 mM. The reaction mixture was concentrated by precipitation with ethanol and redissolved in 10 ml of 100 mM triethylammonium acetate, pH 7.5. The redissolved RNA 25 was isolated by reverse-phase HPLC on a C₄ column eluted with a gradient of acetonitrile. Fractions containing the RNA product were concentrated by ethanol precipitation.

B. Synthesis of the Oligonucleotide Product

30 A DNA primer (with a 3' terminus consisting of UC, where U is a ribonucleotide, and C is a deoxyribonucleotide) was used which had the sequence given by SEQ. ID. NO. 9. A 9 mL reaction mixture was prepared to contain 130 A₂₆₀ units of primer, 130 A₂₆₀ units of template, 50 mM Tris, pH 8.3, 75 mM KCl, 25 mM NaF, 3 mM MgCl₂, 1 mM DTT, 100 µg/mL BSA, 200 units/ml RNasin, 1 mM dTTPαS, 1 mM dCTPαS and 1 mM dGTPαS (note that 1 mM

5 dATP α S was not required because the desired oligonucleotide consisted only of C, G and T). Then, 3.6 X 10⁶ units of Moloney murine leukemia virus (MMLV) reverse transcriptase was added, and the reaction mixture was incubated for twenty one hours at 37°C.

C. Purification of the Oligonucleotide Product

10 The resulting double stranded product consisting of the primer extension product (SEQ. ID. NO. 10) hybridized to the template was purified by extraction with toluene:phenol (9:1 v/v). The toluene:phenol phase was extracted three times with 10 mM Tris (pH 8.0), and the combined aqueous phases were concentrated by precipitation with ethanol. The ethanol precipitate was redissolved in 1.2 mL 10 mM Tris (pH 8.0), adjusted to 100 mM NaOH, then 15 incubated for 60 minutes at 70°C. This alkaline hydrolysis had a dual function: 1) separating the oligonucleotide product from the primer by cleavage of the phosphodiester bond between the uridine of the primer and the cytidine of 20 the oligonucleotide; and 2) digesting the RNA template.

25 The alkaline-treated material was neutralized with HCl, then the RNA template was treated with 12.5 μ g E. coli RNase A for two hours to achieve more complete digestion of the RNA template. The oligonucleotide product (SEQ. ID. NO. 11) was concentrated by precipitation with ethanol, redissolved in 100 mM triethylammonium acetate, pH 7.5, and isolated by high pressure liquid chromatography on a C₁₈ reverse phase column eluted with acetonitrile using a 0.5% gradient. Peak fractions of the 30 oligonucleotide product were pooled and concentrated by ethanol precipitation, redissolved in sterile phosphate buffered saline, and stored at -20°C.

D. Regeneration and Reuse of the Primer

35 The "used" primer from step C was reused in a subsequent synthesis according to steps A to C above and found to be 28% as active as an unused primer. Treatment

of the used primer with calf intestine alkaline phosphatase resulted in the complete regeneration of the primer, as demonstrated by its reuse in a subsequent synthesis according to steps A to C with 100% the activity of an 5 unused primer.

Example V

Comparison of Oligonucleotide Product to Chemically Synthesized Oligonucleotide

10 In order to compare chemically synthesized oligonucleotides to enzymatically synthesized oligonucleotides, a phosphorothioate oligonucleotide was prepared using automated chemical synthesis (the "control") to have the same sequence as the oligonucleotide product from 15 Example IV (the "product").

A. Comparison of Physiochemical Properties

20 The product appeared as a single band on a 20% denaturing polyacrylamide gel and had an electrophoretic mobility substantially identical to that of the control oligonucleotide. Additionally, the thermal denaturation curves of the product and the control were identical.

25 The product and the control were also compared using nuclear magnetic resonance spectroscopy calibrated with H_3PO_4 . The signal obtained by both exhibited a peak at 55.639 ppm, and the product exhibited an upfield chemical shift which was consistent with the product containing phosphorothioate linkages with the *Rp* configuration.

30 B. Comparative Effect on p24 Production

The product was tested for effectiveness as an antisense agent *in vitro* and compared to the control. T-lymphocytes (SupT-1 from Advanced BioTechnologies, Inc., Columbia, Maryland) were propagated in RPMI 1640 medium 35 supplemented with 10% (v/v) fetal bovine serum and 50 $\mu\text{g}/\text{ml}$ gentamicin sulfate at 37°C in a humidified 5% CO_2 atmosphere. Only cell cultures having viable titers less

than 2×10^6 cells/ml and viability in excess of 90%, as gauged by trypan blue exclusion, were used as hosts for acute infection.

5 Approximately 2.0×10^6 cells were pelleted by centrifugation at about 170g for 8 minutes. The medium was removed and the cells were gently resuspended in fresh medium to a final concentration of about 1×10^6 cells/ml. HIV-1 strain IIIB (1×10^5 TCID₅₀/ml; "TCID" = Tissue Culture Infective Dose), was added to the cells at a 10 multiplicity of infection of 0.04 syncytium-forming units ("sfu") per cell (0.7 sfu = 1.0 TCID₅₀). The virus and cell mixture was incubated for 2 hours at 37°C in a humidified 5% CO₂ atmosphere, and then diluted to 10 ml with medium and pelleted by centrifugation at about 170g 15 for 8 minutes. The pelleted cells were washed three times with 10 ml of medium and then resuspended in medium to a concentration of 1×10^5 cells/ml.

20 Cells were dispensed in 100 μ l volumes to round bottom wells of 96-well plates containing an equal volume of medium with various concentrations of product or control oligonucleotide, as well as a "no oligonucleotide" blank. Each concentration was tested at least twice. The plates were incubated at 37°C in a humidified 5% CO₂ atmosphere. After 7 days, the cells in each culture were 25 pelleted *in situ* by centrifuging the incubation plate at about 170g for 8 minutes. One hundred μ l of the supernatant from each well was transferred to a new 96-well plate and frozen at -80°C for later p24 core antigen level determination.

30 The supernatants were allowed to thaw at room temperature and diluted to various levels in fresh medium. HIV-1 p24 antigen levels were determined using a capture ELISA purchased from Coulter Corporation (Hialeah, Florida). The kinetic assay format was used and carried 35 out according to the manufacturer's instructions. The effect on p24 antigen production was virtually the same between the product and the control.

C. Comparative Effect on Formation of Syncitia

The effect of the product and the control on plaque formation was determined as follows: HT-6C cells (clone 6C of Hela cells expressing CD4 from a recombinant retroviral vector, NIH AIDS Research and Reference Reagent Program) were maintained in 75 cm² tissue culture flasks in DMEM medium (Gibco BRL, Gaithersberg, Maryland) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine at 37°C 5 in a humidified 5% CO₂ atmosphere. The cells were detached 10 from the flasks with trypsin-EDTA (GibcoBRL, Gaithersberg, Maryland), collected by centrifugation at 230g and resuspended in the above medium. These cells were plated 15 at 3.2 X 10⁴ cells/well in 48-well tissue culture dishes and grown overnight at 37°C in a humidified 5% CO₂ atmosphere.

To initiate an assay, the medium was removed from each well and 200 µl of HIV (100 to 200 plaque forming units) in DMEM medium supplemented with 4% (v/v) fetal 20 bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine, 8 µg/ml DEAE dextran, and 0.5 µg/ml polybrene were added to each well. The dishes were incubated at 37°C in a humidified 5% CO₂ atmosphere. After 2 hours, 800 µl of medium containing various 25 concentrations of product or control was added to wells, and the dishes were each incubated at 37°C in a humidified 5% CO₂ atmosphere for three days. The medium from each well was then removed and 1 ml of 100% methanol was added to each well to fix the cells to the dishes. After 15 30 minutes, the methanol was removed and 0.5 ml of 0.3% (w/v) crystal violet stain dissolved in phosphate buffered saline was added to each well. After 5 minutes, the wells were rinsed with water, drained and allowed to dry. The number of syncitia (dark staining giant cells) in each 35 well were counted using microscopic examination. The percent reduction in syncitium formation resulting from treatment with various concentrations of the

oligonucleotide product and the control oligonucleotide were virtually the same.

Example VI

5 Synthesis of an Oligonucleotide using a Self-Priming RNA Template

A. Preparation of Template

A template was chosen which would direct the synthesis of an antisense oligonucleotide which was complementary to an mRNA sequence (SEQ. ID No. 2) encoding the HIV REV protein. (See Peterson, et al., *supra*.) Template was prepared by first chemically synthesizing an oligodeoxynucleotide having three subsequences given in 5' to 3' order: a T7 RNA polymerase self-complementary 10 ("hairpin") promotor sequence (SEQ. ID. NO. 12); and a sequence which was complementary to the desired self-priming template (SEQ. ID. NO. 13). The sequence of this 15 oligodeoxynucleotide, which terminated in a 5' non-nucleotide "RXL" linker, is given by SEQ. ID No. 14. (For the precise structure of the RXL linker, see Arnold, et al., PCT WO 89/02439, linker reagent 23 of Example 8(a), 20 incorporated herein by reference).

The *in vitro* transcription from the oligodeoxy-nucleotide was carried out in a 2.0 ml reaction mixture 25 containing 0.252 A₂₆₀ units of the oligodeoxynucleotide in 40 mM Tris (pH 8.0), 20 mM MgCl₂, 4 mM ATP, 4 mM GTP, 4 mM CTP, 4 mM UTP, 1 mM spermidine, 0.08% (w/v) polyethylene glycol (PEG) 8000, 0.01% (w/v) Triton X-100, 5 mM dithiothreitol (DTT), 5 µg/mL bovine serum albumin (BSA), 30 100 units of RNasin (Promega, Inc., Madison, WI), and 24,000 units of T7 RNA polymerase. The reaction mixture was incubated at 37°C for approximately four hours, or until formation of a magnesium pyrophosphate precipitate was observed.

35 The self-priming template thus formed had the sequence given by SEQ. ID. NO. 15, and consisted of two subsequences in 5' to 3' order; the oligonucleotide

complementary region (SEQ. ID. NO. 16) and the self-priming region (SEQ. ID. NO. 17).

The template was isolated by chromatography as follows: The magnesium pyrophosphate precipitate was dissolved by the addition of EDTA to a final concentration of 20 mM. The reaction mixture was concentrated with ethanol, and redissolved in 0.1M triethylammonium acetate, pH 7.5. The redissolved RNA was applied to a Sep-Pak C₁₈ cartridge (Millipore Waters, Milford, MA) and washed with 0.1 M triethylammonium acetate, pH 7.5. The template was eluted with 70% methanol in water, concentrated by vacuum evaporation and redissolved in 0.1 M triethylammonium acetate, pH 7.5. The RNA transcript was further purified by high pressure liquid chromatography.

15

B. Synthesis of Oligonucleotide Product

A 1 mL reaction mixture was prepared to contain 7.45 A₂₆₀ units of self-priming template, 50 mM Tris, pH 8.3, 20 75 mM KCl, 3 mM MgCl₂, 336 units/ml RNasin, 3 mM dTTP α S, 3 mM dCTP α S and 3 mM dGTP α S (note that 1 mM dATP α S was not required because the desired oligonucleotide consisted only of C, G and T). Then, 1.3 X 10⁶ units of Moloney murine leukemia virus (MMLV) reverse transcriptase was added, and the reaction mixture was incubated for seven 25 hours at 37°C.

Example VII

Synthesis of a Plurality of Oligonucleotides from a Single Template

30 A. Preparation of Template

A template was chosen which would direct the synthesis of an antisense oligonucleotide which was complementary to an mRNA sequence (SEQ. ID No. 18) encoding the HIV REV protein. (See Peterson, et al., 35 supra.) Template was prepared by first chemically synthesizing an oligodeoxynucleotide having two subsequences; a T7 RNA polymerase promotor sequence (SEQ.

ID. No. 19), and a sequence (SEQ. ID. No. 20) which was complementary to the desired template, and which consisted of three repeated subsequences. The sequence of this oligodeoxynucleotide is given by SEQ. ID No. 21.

5 The *in vitro* transcription from the oligodeoxynucleotide was carried out in a 0.1 ml reaction mixture containing 0.003 A₂₆₀ units of the oligodeoxynucleotide in 40 mM Tris (pH 8.0), 20 mM MgCl₂, 4 mM ATP, 4 mM GTP, 4 mM CTP, 4 mM UTP, 1 mM spermidine, 0.08% (w/v) polyethylene 10 glycol (PEG) 8000, 0.01% (w/v) Triton X-100, 5 mM dithiothreitol (DTT), 50 µg/mL bovine serum albumin (BSA), and 600 units of T7 RNA polymerase. The reaction mixture was incubated at 37°C for three hours. The reaction was stopped by heating for 10 minutes at 70°C. After cooling 15 to 0°C, 80 units of RNasin (Promega, Inc., Madison, WI) were added.

The template thus formed had the sequence given by SEQ. ID. NO. 22.

20 B. Synthesis of Oligonucleotide Product

The template was reverse transcribed without further purification. A 10 µl aliquot of the reaction mixture was added to a synthesis reaction mixture containing 19 ng dT₁₀ primer, 50 mM Tris HCl (pH 8.3), 75 mM KCl, 3 mM MgCl₂, 2 mM dATP α S, 2 mM dTTP α S, 2 mM dGTP α S, 2 mM dCTP α S, and 80 units of RNasin. To this synthesis reaction mixture was added RNase H free MMLV reverse transcriptase (Gibco BRL, Bethesda, MD) to a total volume of 100 µl. This oligonucleotide product precursor thus formed was purified 25 on a NENSORB 20 cartridge (DuPont NEN, Boston, MA) according to manufacturer's instructions. This was followed by cleavage into individual oligonucleotides by treatment with 35 units of Hae III (New England Biolabs, Beverly, MA) and 1 µg RNase (DNase-free, Boehringer- 30 Mannheim, Indianapolis, IN) in Restriction Buffer 2 (New England Biolabs, Beverly, MA) for 22 hours at 37°C. The 35

sequence of the oligonucleotide product is given in SEQ. ID. NO. 23.

Although the invention has been described in terms of specific embodiments, many modifications and variations of 5 the present invention are possible in light of the teachings. It is, therefore, to be understood that within the scope of the appended claims the invention may be practiced otherwise than as specifically described.

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: GEN-PROBE INCORPORATED

(ii) TITLE OF INVENTION: TEMPLATE AND PRIMER BASED
SYNTHESIS OF ENZYMATICALLY
CLEAVABLE OLIGONUCLEOTIDES

(iii) NUMBER OF SEQUENCES: 23

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Lyon & Lyon
(B) STREET: 633 West Fifth Street, Suite
4700
(C) CITY: Los Angeles
(D) STATE: California
(E) COUNTRY: USA
(F) ZIP: 90071-2066

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: MS-DOS (Version 6.22)
(D) SOFTWARE: Word Perfect (Version 5.1)

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

Prior applications total,
including application
described below:

5

(A) APPLICATION NUMBER: 08/484,519
(B) FILING DATE: 06/07/95
(C) APPLICATION NUMBER: 08/484,668
(D) FILING DATE: 06/07/95
(E) APPLICATION NUMBER: 08/484,816
(F) FILING DATE: 06/07/95
(G) APPLICATION NUMBER: 08/476,626
(H) FILING DATE: 06/07/95
(I) APPLICATION NUMBER: 08/477,228
(J) FILING DATE: 06/07/95

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Schneider, Carol A.
 (B) REGISTRATION NUMBER: 34,923
 (C) REFERENCE/DOCKET NUMBER: 219/070-PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (213) 489-1600
 (B) TELEFAX: (213) 955-0440
 (C) TELEX:

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 90 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GAAGCCCGGA CAGCCCAGGG GAGCCCGGCC AGGCGCTCGA GAAGCCCGGA 50
 CAGCCCAGGG GAGCCCTCGC CTATTGTTAA AGTGTGTCCT 90

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CCCGAGGGGA CCCGACAGGC CCGAAG

26

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TATAGTGAGT CGTATTATTT TTAATACGAC TCACTATA

38

45

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	39 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GACGGCACCT CTTGGGCCT GTGGGTCCC CTCGGGCC

39

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	77 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GACGGCACCT CTTGGGCCT GTGGGTCCC CTCGGGCC 50
GTATTATTT TAATACGACT CACTATA 77

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	39 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GGGCCGAGG GGACCCGACA GGCGAAGA GGTGCCGTC

39

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	10 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

AGGTGCCGTC

10

46

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	29 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGGCCCGAGG GGACCCGACA GGCCCGAAG

29

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	11 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GACGGCACCU C

11

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	39 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GACGGCACCT CTTCGGGCCT GTCGGGTCCC CTCGGGCC

39

2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	29 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CTTCGGGCCT GTCGGGTCCC CTCGGGCC

29

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	40 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

TATAGTGAGT CGTATTATTT TTAATACGAC TCACTATAGC

40

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	55 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

AAAAAAAAAA GCTTCGTTT TTTTTTCTT CGGGCCTGTC GGGTCCCCTC 50
GGGGC 55

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	95 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

AAAAAAAAAA GCTTCGTTT TTTTTTCTT CGGGCCTGTC GGGTCCCCTC 50
GGGGCTATAG TGAGTCGTAT TATTTTTAAT ACGACTCACT ATAGC 95

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	55 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

GCCCGAGGG GACCCGACAG GCCCGAAGAA AAAAAAAACG AAAGCTTTTT 50
TTTTT 55

48

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	28 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GCCCGAGGG GACCCGACAG GCCCGAAG

28

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	27 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

AAAAAAAAAA CGAAAGCUUU UUUUUUUU

27

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	14 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GGGACCCGAC AGGC

14

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	40 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

TATAGTGAGT CGTATTATTT TTAATACGAC TCACTATAGC

40

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

49

(A)	LENGTH:	70 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

TTTTTTTTTTT GGCCGCCTGT CGGGTCCC GG CCGCCTGTCG GGTCCCGGCC 50
GCCTGTCGGG TCCCGGCCGC 70

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	110 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

TTTTTTTTTTT GGCCGCCTGT CGGGTCCC GG CCGCCTGTCG GGTCCCGGCC 50
GCCTGTCGGG TCCCGGCCGC TATA GTGAGT CGTATTATTT TTAATACGAC 10
TCACTATAGC
110

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	70 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GC GGCCGGGA CCCGACAGGC GGCCGGGACC CGACAGGC GG CCGGGACCCG 50
ACAGGGCGGCC AAAAAAAA 0

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

(A)	LENGTH:	18 base pairs
(B)	TYPE:	nucleic acid
(C)	STRANDEDNESS:	single
(D)	TOPOLOGY:	linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

CCGGGACCCG ACAGGGCGG

18

Claims

1. A method of synthesizing at least one chirally pure oligonucleotide comprising the steps of:
 - (a) providing a nucleic acid template, the template comprising a primer binding region and an oligonucleotide complementary region located 5' to said primer binding region;
 - (b) contacting the template with a nucleic acid primer able to hybridize to the primer binding region of said template to form a template-primer hybrid;
 - 10 (c) incubating the template-primer hybrid in the presence of at least one DNA polymerase under conditions in which DNA synthesis occurs to form a primer extension product;
 - (d) cleaving the primer extension product to separate the primer from the oligonucleotide or oligonucleotides and, if necessary, to separate the oligonucleotides from each other; and
 - (e) before, simultaneous with or subsequent to step 15 (d), digesting the template.
- 20 2. The method of claim 1 wherein the oligonucleotide or oligonucleotides are modified.
3. The method of claim 2 wherein the oligonucleotide or oligonucleotides are phosphorothioate oligonucleotides or phosphorothioate-containing oligonucleotides.
- 25 4. The method of claim 1 wherein the template is RNA.
5. The method of claim 1 wherein the template is DNA.
- 30 6. The method of claim 1 wherein the oligonucleotide complementary region comprises more than

one subregion, each said subregion being separated from adjacent subregions by a cleavage site, and said template is used to direct the synthesis of a primer extension product which is able to be cleaved to form two or more 5 oligonucleotides having the same or different lengths and/or sequences.

7. The method of claim 1 wherein the primer extension product is separated from the primer by at least one restriction endonuclease recognition sequence and 10 cleavage of the primer extension product from the primer is achieved by cleaving with a restriction endonuclease able to recognize said restriction endonuclease recognition sequence.

8. The method of claim 6 wherein the primer extension product is separated from the primer by at least 15 one restriction endonuclease recognition sequence and cleavage of the primer extension product from the primer is achieved by cleaving with a restriction endonuclease able to recognize said restriction endonuclease recognition sequence.

9. The method of claim 1 wherein the primer is DNA with at least one ribonucleotide at or near its 3'-terminus.

10. The method of claim 9 wherein cleavage of the 25 primer extension product to separate the primer from the oligonucleotide is achieved using alkaline hydrolysis or enzymatic degradation of RNA.

11. The method of claim 9 wherein cleavage of the 30 primer extension product to separate the primer from the oligonucleotide is achieved using alkaline hydrolysis and enzymatic degradation of RNA.

12. The method of claim 1 wherein the primer contains at least one deoxyuridine at or near its 3'-terminus.

5 13. The method of claim 12 wherein cleavage of the primer extension product from the primer is achieved with a DNA glycosylase and an AP-endonuclease.

10 14. The method of claim 1 wherein both template and primer are contained on a single nucleic acid strand, said template being a self-priming template comprising a self-complementary region and an oligonucleotide complementary region and the primer comprises the 3'-terminus of the self-complementary region.

15. The method of claim 9 wherein the primer has a single ribonucleotide at or near its 3'-terminus.

15 16. The method of claim 4 wherein step (e) is achieved using alkaline hydrolysis or enzymatic degradation of RNA.

20 17. The method of claim 4 wherein step (e) is achieved using alkaline hydrolysis and enzymatic degradation of RNA.

18. The method of claim 1 wherein the primer comprises the primer complementary region of a second template.

19. The method of claim 4 wherein said template is digested using an RNase H activity.

5 20. The method of claim 19 wherein said primer is separated from said oligonucleotide using an RNase H activity.

21. The method of claim 6 wherein the cleaving agent used to separate the primer from the oligonucleotide is different from the cutting agent able to separate said oligonucleotide subregions.

5 22. The method of claim 3 wherein the oligonucleotide is a chirally pure phosphorothioate oligonucleotide.

23. A method of synthesizing two or more oligonucleotides comprising the steps of:

10 (a) providing a nucleic acid template, the template comprising a primer binding region and an oligonucleotide complementary region located 5' to said primer binding region, wherein the oligonucleotide complementary region comprises more than one subregion, each said subregion being separated from adjacent subregions by a cleavage site, and said template is used to direct the synthesis of a primer extension product which is able to be cleaved to form two or more oligonucleotides having the same or different lengths and/or sequences;

15 20 (b) contacting the template with a nucleic acid primer able to hybridize to the template to form a template-primer hybrid;

25 (c) incubating the template-primer hybrid in the presence of at least one DNA polymerase under conditions in which DNA synthesis occurs to form a primer extension product; and

(d) cleaving the primer extension product to separate the primer and the oligonucleotides from each other.

5 24. The method of claim 23 wherein the oligonucleotides are modified.

25. The method of claim 24 wherein the oligonucleotides are phosphothiorate oligonucleotides or phosphothiorate-containing oligonucleotides.

5 26. The method of claim 23 wherein the template is RNA.

27. The method of claim 23 wherein the template is DNA.

10

28. The method of claim 23 wherein the primer extension product contains at least one cleavage site which comprises a restriction endonuclease recognition sequence and said primer extension product is cleaved 15 using a restriction endonuclease able to recognize the restriction endonuclease recognition sequence.

20 29. The method of claim 23 wherein said cleavage sites comprise at least one restriction endonuclease recognition sequence and the primer extension product is cleaved using a restriction endonuclease able to recognize the restriction endonuclease recognition sequence.

25 30. The method of claim 23 wherein the primer is DNA with at least one ribonucleotide at or near its 3'-terminus.

30 31. The method of claim 30 wherein cleavage of the primer extension product to separate the primer from the oligonucleotides is achieved using alkaline hydrolysis or enzymatic degradation of RNA.

35 32. The method of claim 30 wherein cleavage of the primer extension product to separate the primer from the oligonucleotide is achieved using alkaline hydrolysis and enzymatic degradation of RNA.

33. The method of claim 23 wherein the primer contains at least one deoxyuridine at or near its 3'-terminus.

5 34. The method of claim 33 wherein the primer extension product is cleaved to separate the primer from the oligonucleotides and said cleavage is achieved using a DNA glycosylase and an AP-endonuclease.

10 35. The method of claim 23 wherein both template and primer are contained on a single nucleic acid strand, said template being a self-priming template comprising a self-complementary region and an oligonucleotide complementary region and the primer comprises the 3'-terminus of the 15 self-complementary region.

36. The method of claim 31 wherein the primer has a single ribonucleotide at or near its 3'-terminus.

20 37. The method of claim 26 wherein the template is digested before, simultaneous with or subsequent to step (d) using alkaline hydrolysis or enzymatic degradation of RNA.

25 38. The method of claim 26 wherein cleavage of the primer extension product to separate the primer from the oligonucleotide is achieved using alkaline hydrolysis and enzymatic degradation of RNA.

30 39. The method of claim 38 wherein the template is digested using alkaline.

35 40. The method of claim 23 wherein the primer complementary region of a second template comprises the primer.

41. The method of claim 1 wherein said primer extension product is cleaved to yield said primer and an oligonucleotide containing said cleavage sites, and wherein two or more cleavage sites require cleavage by 5 different cleaving agents.

42. The method of claim 1 wherein at least a portion of said oligonucleotide complementary region resists cleavage by at least one cleaving agent.

10

43. The method of claim 19 wherein said primer extension product is cleaved at one or more cleavage site using RNase H activity.

15

44. A method of cleaving a phosphorothioate oligonucleotide or phosphorothioate-containing oligonucleotide having the nucleic acid restriction endonuclease recognition sequence 5'-GGCC-3' comprising contacting the phosphorothioate oligonucleotide or 20 phosphorothioate-containing oligonucleotide with an effective amount of restriction endonuclease Hae III under conditions in which said restriction endonuclease is active.

25

45. A method of cleaving a phosphorothioate oligonucleotide or phosphorothioate-containing oligonucleotide having the nucleic acid restriction endonuclease recognition sequence 5'-GCGC-3' comprising - contacting the phosphorothioate oligonucleotide or 30 phosphorothioate-containing oligonucleotide with an effective amount of restriction endonuclease HinP I under conditions in which said restriction endonuclease is active.

35

46. A method of cleaving a phosphorothioate oligonucleotide or phosphorothioate-containing oligonucleotide having the nucleic acid restriction

5 endonuclease recognition sequence 5'-CCNGG-3' comprising
contacting the phosphorothioate oligonucleotide or
phosphorothioate-containing oligonucleotide with an
effective amount of restriction endonuclease ScrF I under
conditions in which said restriction endonuclease is
active.

10 47. A method of cleaving a phosphorothioate
oligonucleotide or phosphorothioate-containing
oligonucleotide having the nucleic acid restriction
endonuclease recognition sequence 5'-TCGA-3' comprising
contacting the phosphorothioate oligonucleotide or
phosphorothioate-containing oligonucleotide with an
effective amount of restriction endonuclease Taq^a I under
15 conditions in which said restriction endonuclease is
active.

20 48. A method of synthesizing at least one
phosphorothioate oligonucleotide or phosphorothioate-
containing oligonucleotide comprising the steps of:

(a) providing a nucleic acid template, the template
comprising a primer binding region and an oligonucleotide
complementary region;

25 (b) contacting the template with a nucleic acid
primer able to hybridize to the primer binding region to
form a template-primer hybrid;

30 (c) incubating the template-primer hybrid in the
presence of at least one DNA polymerase under conditions
in which DNA synthesis occurs to form a primer extension
product, wherein the primer extension product comprises at
least one restriction endonuclease recognition sequence
selected from the group consisting of 5'-GGCC-3', 5'-GCGC-
3', 5'-CCNGG-3', 5'-TCGA-3' wherein N is any nucleotide;
and

35 (d) cleaving the primer extension product to
separate the primer from the oligonucleotide or the
oligonucleotides from each other, wherein at least one

cleavage is accomplished by contacting the primer extension product with an effective amount of a restriction endonuclease capable of recognizing the restriction endonuclease recognition sequence selected 5 from the group consisting of Hae III, HinP I, ScrF I and Taq^a I.

49. The method of claim 48 wherein the restriction endonuclease recognition sequence is 5'-GGCC-3' and the 10 restriction endonuclease is Hae III.

50. The method of claim 48 wherein the restriction endonuclease recognition sequence is 5'-GCGC-3' and the restriction endonuclease is HinP I.

15 51. The method of claim 48 wherein the restriction endonuclease recognition sequence is 5'-CCNGG-3' and the restriction endonuclease is ScrF I.

20 52. The method of claim 48 wherein the restriction endonuclease recognition sequence is 5'-TCGA-3' and the restriction endonuclease is Taq^a I.

25 53. The method of claim 48 wherein the template is RNA.

. 54. The method of claim 48 wherein the template is DNA.

30 55. The method of claim 48 wherein the oligonucleotide complementary region comprises more than one subregion separated from other subregions by a cleavage site and said template is used to direct the synthesis of two or more oligonucleotides having the same 35 or different lengths and/or sequences.

56. The method of claim 48 wherein the primer is DNA with at least one ribonucleotide at or near its 3'-terminus.

5 57. The method of claim 56 wherein cleavage of the primer extension product to separate the primer from the oligonucleotide or oligonucleotides is achieved using alkaline hydrolysis or enzymatic degradation of RNA.

10 58. The method of claim 48 wherein the primer contains at least one deoxyuridine at or near its 3'-terminus.

15 59. The method of claim 58 wherein the primer extension product is cleaved to separate the primer from the oligonucleotide or oligonucleotides and said cleavage is achieved using a DNA glycosylase and an AP-endonuclease.

20 60. The method of claim 48 wherein both template and primer are contained on a single nucleic acid strand, said template being a self-priming template comprising a self-complementary region and an oligonucleotide complementary region and the primer comprises the 3'-terminus of the 25 self-complementary region.

30 61. The method of claim 48 wherein the template is digested before, simultaneous with or subsequent to step (d) using alkaline hydrolysis or enzymatic degradation of RNA.

62. The method of claim 61 wherein the template is digested using alkaline.

35 63. The method of claim 48 wherein the primer comprises the primer complementary region of a second template.

64. A method of synthesizing at least one oligonucleotide comprising the steps of:

(a) providing a nucleic acid template, the template comprising a primer binding region and an oligonucleotide complementary region located 5' to said primer binding region;

5 (b) contacting the template with a nucleic acid primer able to hybridize to the template to form a template-primer hybrid, wherein the primer comprises DNA with at least one ribonucleotide at or near its 3'-terminus;

10 (c) incubating the template-primer hybrid in the presence of at least one DNA polymerase under conditions in which DNA synthesis occurs to form a primer extension product;

15 (d) cleaving the primer extension product to yield the primer and the oligonucleotide or oligonucleotides by hydrolyzing the internucleotide phosphate linkage(s) in the 3' direction from the ribonucleotide(s); and

20 (e) repeating steps (b) and (c) at least once using the primer from step (d).

65. The method of claim 64 wherein the oligonucleotide or oligonucleotides are modified to be 25 more resistant to at least one nuclease than an unmodified oligonucleotide having the same nucleotide sequence.

66. The method of claim 65 wherein the oligonucleotide or oligonucleotides are phosphorothioate 30 oligonucleotides or phosphorotioate-containing oligonucleotides.

67. The method of claim 64 wherein the template is RNA.

35

68. The method of claim 64 wherein the template is DNA.

69. The method of claim 64 wherein the oligonucleotide complementary region comprises more than one subregion, each said subregion being separated from adjacent subregions by a cleavage site, and said template is used to direct the synthesis of a primer extension product which is able to be cleaved to form two or more oligonucleotides having the same or different lengths and/or sequences.

10

70. The method of claim 69 wherein the primer extension product comprises at least one restriction endonuclease recognition sequence and cleavage of the primer extension product to separate the oligonucleotides from each other is achieved using a restriction endonuclease able to recognize the restriction endonuclease recognition sequence.

20

71. The method of claim 64 wherein cleavage of the primer extension product to separate the primer from the oligonucleotide or oligonucleotides is achieved using alkaline hydrolysis or enzymatic degradation of RNA.

25

72. The method of claim 64 wherein cleavage of the primer extension product to separate the primer from the oligonucleotide or oligonucleotides is achieved using alkaline hydrolysis and enzymatic degradation of RNA.

30

73. The method of claim 64 wherein both the template and primer are contained on a single nucleic acid strand, said template being a self-priming template comprising a self-complementary region and an oligonucleotide complementary region and the primer comprises the 3'-terminus of the self-complementary region.

35

74. The method of claim 64 wherein the primer has a single ribonucleotide at or near its 3'-terminus.

62

75. The method of claim 67 wherein the template is digested before, simultaneous with, or subsequent to, step (d) using alkaline.

5 76. The method of claim 64 wherein the primer comprises the primer complementary region of a second template.

1/7

FIG. 1a.




FIG. 1b.





FIG. 1c.



SUBSTITUTE SHEET (RULE 26)

FIG. 2a.




FIG. 2b.






FIG. 2c.



3/7


FIG. 3.



SUBSTITUTE SHEET (RULE 26)


4/7

FIG. 4.




SUBSTITUTE SHEET (RULE 26)

FIG. 5.




6/7

FIG. 6.



7/7

FIG. 7.



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/07082

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/10 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 08296 (ISIS PHARMACEUTICALS INC.) 29 April 1993	64-68,70
A	see page 35, line 19 - page 40, line 7; figures 53,54 ---	1-22, 48-63
Y	WO,A,92 05287 (AMGEN INC.) 2 April 1992	64-68,
A	cited in the application	71-74 1-43, 48-63
	see page 7, line 18 - page 8, line 2 see page 11, line 11 - line 25 see page 16, line 33 - page 18, line 14 see page 19, line 19 - page 20, line 11 see page 23, line 9 - line 28 see page 30, line 20 - page 31, line 9 ---	
		-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *'A' document defining the general state of the art which is not considered to be of particular relevance
- *'E' earlier document but published on or after the international filing date
- *'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *'O' document referring to an oral disclosure, use, exhibition or other means
- *'P' document published prior to the international filing date but later than the priority date claimed

*'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

*'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

*'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

*'&' document member of the same patent family

2

Date of the actual completion of the international search

Date of mailing of the international search report

1 October 1996

14.10.96

Name and mailing address of the ISA

Authorized officer

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.
Fax (+ 31-70) 340-3016

Montero Lopez, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/07082

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 496 483 (INTEGRATED DNA TECHNOLOGIES, INC.) 29 July 1992 cited in the application see page 3, line 38 - page 4, line 14 ---	64-68, 71-74
A	NUCLEOSIDES & NUCLEOTIDES, vol. 10, no. 1-3, 1991, pages 665-667, XP000603015 D.B. OLSEN ET AL.: "Interaction of restriction endonucleases with phosphorothioate-containing DNA" see the whole document ---	44-47
E	WO,A,96 19572 (HYBRIDON INC ;TANG JINYAN (US); ROSKEY ALLYSEN M (US); AGRAWAL SUD) 27 June 1996 see page 3, line 6 - page 5, line 7 see page 8, line 24 - page 10, line 21 -----	64-68, 71-75

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/07082

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9308296	29-04-93	US-A-	5212295	18-05-93
		AU-A-	2874892	21-05-93
		EP-A-	0655088	31-05-95
		JP-T-	6511492	22-12-94
		US-A-	5506212	09-04-96
		US-A-	5521302	28-05-96
-----	-----	-----	-----	-----
WO-A-9205287	02-04-92	AU-B-	648842	05-05-94
		AU-A-	8844691	15-04-92
		CA-A-	2069096	22-03-92
		EP-A-	0502180	09-09-92
		JP-T-	5502594	13-05-93
-----	-----	-----	-----	-----
EP-A-496483	29-07-92	AU-A-	1004292	30-07-92
		CA-A-	2058232	23-07-92
		JP-A-	5070477	23-03-93
-----	-----	-----	-----	-----
WO-A-9619572	27-06-96	AU-A-	4514696	10-07-96
-----	-----	-----	-----	-----